How we make an impact

Aligned with United Nations Sustainability goals 3, 8, and 17, we strive to make a difference in combating primary health challenges in low and middle income countries. Our efforts focus on the following areas:

Improving Patient outcomes

Providing treatments at access prices and co-designing programs with public & NGO partners.

Building impactful multisectoral partnerships

Financing programs with public & NGO partners and supporting the scale-up of social businesses, including equity investments.

Strengthening Health Systems

Providing non-financial support, technical assistance & mentorship through employee engagement.

The Impact Brand

The Impact brand is focused on health care for non-communicable diseases (NCDs), such as cardiovascular diseases, cancers, and diabetes, in selected countries where we operate across the globe.

 The challenge of NCDs

Each year, 17 million people die from an NCD before the age of 70 and 86% of these premature deaths occur in low and middle income countries.1

    • NCD treatments are long and costly and they contribute to poverty due to substantial medical costs and high out-of-pocket expenditure.
    • People in low and middle income countries have less access to effective and equitable healthcare services, leading to late detection of diseases and a higher risk of premature deaths.

How we address the challenge

To address the health challenges of NCDs in developing countries, the Global Health Unit of Sanofi has developed an accessible solution bringing to market several standard-of-care NCD treatments under the brand name of Impact (INN + Impact).

The provision of the Impact range by GHU countries will replace pre-existing identical heritage Sanofi brands for these conditions.

 Same quality, different name

With no compromise on quality, the only thing that changes from the Sanofi product brands to the Impact brand is the name and packaging.

    Launching Impact instead of original Sanofi brands enables us to:

    • Provide more accessible prices for these essential medicines, thus offering more value to reach more patients
    • Employ one unique pack across countries where we operate to help prevent parallel trade

    For more information about this change, visit our FAQ

SEE OUR IMPACT PRODUCTS

Jon Fairest
Head of Global Health Unit, Sanofi

 We are working to improve access to essential medicines while supporting quality and sustainable healthcare for people in countries with the highest unmet medical needs. It's critical that we work with global, regional and local partners, to bring transformative and lasting change. By building end-to-end health programs that are embedded in the communities they serve, we have the greatest opportunity to improve care and create a more resilient world  

How we work

Discover the core of what we do to address NCDs health challenges and improve care for patients.

Have a question
or need support?  

Find answers to the most common questions in our FAQ. Maybe your question has already been asked. If you don't find your answer, you're always welcome to contact us.

SEARCH THE FAQ
CONTACT US

References

  1. WHO. https://www.who.int/news-room/fact-sheets/detail/noncommunicable-diseases, Last accessed September 2023.

MAT-GLB-2304595 (v3.0)
DOP: April 2024